Compare INSG & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | TLSA |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 182.7M |
| IPO Year | 2000 | 2000 |
| Metric | INSG | TLSA |
|---|---|---|
| Price | $11.40 | $1.62 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.33 | N/A |
| AVG Volume (30 Days) | 167.7K | ★ 310.3K |
| Earning Date | 02-19-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $165,876,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.24 | $0.63 |
| 52 Week High | $18.11 | $2.60 |
| Indicator | INSG | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 52.75 |
| Support Level | $11.49 | $1.36 |
| Resistance Level | $12.71 | $1.75 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 55.38 | 69.77 |
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.